Cardiol Therapeutics Inc.

CRDL on TSXToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
2.91CAN 3.93%42,1001.8700 - 5.000095.403M
CRTPF on OTCQXToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
2.19US 4.29%28,7871.0800 - 3.830072.484M

Contact Information

Cardiol Therapeutics Inc.

Headquarters:
2265 Upper Middle Road East , Suite 602
Oakville, Ontario
Canada, L6H 0G5
Tel: (289) 910-0850
Email: Send a message
Website: Visit website
For more information...
Lead: Daniel Gordon

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is focused on producing pharmaceutical cannabidiol (CBD) products for commercialization and supporting the development of innovative therapies for heart diseases, including acute myocarditis and other causes of heart failure. The Company’s lead product, CardiolRx™, is pharmaceutically produced, manufactured under cGMP, and is THC free (<5 ppm). The Company plans to commercialize CardiolRx in the billion-dollar market for medicinal cannabinoids in Canada.

Cardiol is planning an international clinical study of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The Company is also developing proprietary cannabidiol formulations for the treatment of inflammation in the heart that is associated with the development and progression of heart failure. Heart failure is the leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion. For further information about Cardiol Therapeutics, please visit cardiolrx.com.
 

David Elsley, MBA - President and Chief Executive Officer

Eldon R. Smith, OC, LLD (Hon), MD, FCAHS, FCCS, FRCPC - Chief Medical Officer

Chris Waddick, MBA, CPA, CMA - Chief Financial Officer

Thomas Moffatt, BBA - Chief Commercial Officer

Anthony E. Bolton, BSc, PhD, DSc - Director of Research

Andrea B. Parker, MSc, PhD - Director of Clinical Affairs

Anne Tomalin, BA, BSc, RAC - Director of Regulatory Affairs

Blagoja Ristevski, BSc, CHE - Director of Chemical Engineering and Manufacturing

Dolly Kao, BSc, JD - Intellectual Property Counsel

David Elsley, MBA - President and Chief Executive Officer

Eldon R. Smith, OC, LLD (Hon), MD, FCAHS, FCCS, FRCPC - Chairman and Chief Medical Officer

Guillermo Torre-Amione, MD, PhD - Director

Deborah Brown, MBA - Director

Peter Pekos , BSc, MSc - Director

Colin G. Stott, BSc (Hons) - Director

Iain Chalmers, MBA - Director

Stock Information

Company Overview

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is focused on producing pharmaceutical cannabidiol (CBD) products for commercialization and supporting the development of innovative therapies for heart diseases, including acute myocarditis and other causes of heart failure. The Company’s lead product, CardiolRx™, is pharmaceutically produced, manufactured under cGMP, and is THC free (<5 ppm). The Company plans to commercialize CardiolRx in the billion-dollar market for medicinal cannabinoids in Canada.

Cardiol is planning an international clinical study of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The Company is also developing proprietary cannabidiol formulations for the treatment of inflammation in the heart that is associated with the development and progression of heart failure. Heart failure is the leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion. For further information about Cardiol Therapeutics, please visit cardiolrx.com.
 

Management

David Elsley, MBA - President and Chief Executive Officer

Eldon R. Smith, OC, LLD (Hon), MD, FCAHS, FCCS, FRCPC - Chief Medical Officer

Chris Waddick, MBA, CPA, CMA - Chief Financial Officer

Thomas Moffatt, BBA - Chief Commercial Officer

Anthony E. Bolton, BSc, PhD, DSc - Director of Research

Andrea B. Parker, MSc, PhD - Director of Clinical Affairs

Anne Tomalin, BA, BSc, RAC - Director of Regulatory Affairs

Blagoja Ristevski, BSc, CHE - Director of Chemical Engineering and Manufacturing

Dolly Kao, BSc, JD - Intellectual Property Counsel

Board of Directors

David Elsley, MBA - President and Chief Executive Officer

Eldon R. Smith, OC, LLD (Hon), MD, FCAHS, FCCS, FRCPC - Chairman and Chief Medical Officer

Guillermo Torre-Amione, MD, PhD - Director

Deborah Brown, MBA - Director

Peter Pekos , BSc, MSc - Director

Colin G. Stott, BSc (Hons) - Director

Iain Chalmers, MBA - Director

Contact Information

Headquarters:
2265 Upper Middle Road East , Suite 602
Oakville, Ontario
L6H 0G5, Canada
Telephone: (289) 910-0850
Email: Send a message
Website: Visit website